{
    "nctId": "NCT00370552",
    "briefTitle": "A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer",
    "officialTitle": "A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as First Line Therapy for Locally Recurrent or Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 136,
    "primaryOutcomeMeasure": "Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) While On-study",
    "eligibilityCriteria": "Inclusion criteria:\n\n* Locally recurrent or metastatic breast cancer, previously untreated with chemotherapy for advanced disease.\n* At least 1 target lesion per RECIST criteria. Locally recurrent disease must not be amenable to resection with curative intent.\n* No previous cytotoxic chemotherapy for locally recurrent/metastatic disease.\n* Relapse 12 months or more after completing prior adjuvant or neoadjuvant taxane therapy.\n* No previous breast cancer known to overexpress or amplify the human epidermal growth factor receptor 2 gene.\n* Prior hormonal therapy in adjuvant, recurrent, or metastatic setting allowed but must have been discontinued at least 2 weeks before randomization.\n* Karnofsky performance status of 80 to 100 or Eastern Cooperative Oncology Group performance status of 0 to 1.\n* Estimated life expectancy of at least 12 weeks.\n* Recovery from recent therapy (except for alopecia), including chemotherapy, immunotherapy, biologic therapy, or investigational product. Any such therapy must have been completed at least 3 weeks before randomization and at least 6 weeks from use of nitrosourea, or mitomycin.\n* Recovery from recent surgery and radiation therapy. At least 1 week since minor surgery and/or focal/palliative radiation therapy; at least 3 weeks from radiation; at least 4 weeks from major surgery; and at least 8 weeks from liver resection, thoracotomy, or neurosurgery.\n* Absolute neutrophil count \u22651500/mm\\^3.\n* Hemoglobin \u22659 g/dL.\n* Platelets \u2265100,000/mm\\^3.\n* Total bilirubin \u22641.5 times the upper limit of normal (ULN).\n* Aspartate aminotransferase or alanine aminotransferase \u22642.5\\*ULN.\n* Normal partial thromboplastin time and either international normalized ratio or prothrombin time \\<1.5\\*ULN.\n* Serum creatinine \u22641.5\\*ULN or 24-hour creatinine clearance \\>60 mL/min.\n* Urine dipstick for proteinuria \\<2+ (negative, trace, or +1). Participants with \u22652+ proteinuria at baseline were to undergo 24-hour urine collection and demonstrate \u22641g of protein in 24 hours to be eligible.\n\nExclusion criteria:\n\n* Women of child-bearing potential (WOCBP) unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 6 months after treatment with bevacizumab.\n* Women who were pregnant or breastfeeding.\n* Women with a positive pregnancy test on enrollment or prior to study drug administration.\n* Sexually active fertile men, whose partners were WOCBP, not using an adequate method of birth control.\n* Evidence of baseline sensory or motor neuropathy.\n* Serious infection or nonmalignant medical illnesses uncontrolled or the control of which could be jeopardized by this therapy.\n* History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, serious gastric ulcer, or bone fracture within 6 months of study entry.\n* History of hypertensive crisis or hypertensive encephalopathy.\n* Significant vascular disease.\n* Clinically significant cardiovascular disease.\n* Baseline left ventricular ejection fraction by multiple-gated acquisition scan or echocardiogram for subjects with prior exposure to anthracyclines not within institutional normal limits.\n* Symptomatic peripheral vascular disease.\n* History of high dose chemotherapy with bone marrow transplant or peripheral blood stem cell transplant within the previous 2 years.\n* Evidence of bleeding diathesis or coagulopathy.\n* Prior treatment with an epothilone or any antiangiogenic agent.\n* Concurrent nonhealing wound, ulcer, or fracture.\n* Any current or history of brain and/or leptomeningeal metastases. Psychiatric disorders or other conditions rendering the participant incapable of complying with the requirements of the protocol.\n* Any concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix.\n* Known allergy to any of the study drugs or their excipients.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}